ivaltinostat

Ivaltinostat is a small molecule histone deacetylase (HDAC) inhibitor developed by CrystalGenomics and its subsidiaries, including CG Pharmaceuticals and Machaon Biotherapeutics. As an epigenetic modulator, it inhibits the enzymatic activity of HDACs, leading to increased histone acetylation, altered gene expression, and the induction of apoptosis in malignant cells. Ivaltinostat is being investigated for the treatment of several cancers, most notably metastatic pancreatic adenocarcinoma, where it is often evaluated in combination with chemotherapeutic agents like capecitabine or gemcitabine. It has also been studied for myelodysplastic syndrome (MDS), liver cancer, and other solid tumors. The drug is developed in both intravenous and oral (capsule) formulations to provide flexible dosing options.

Other names

(E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate